TY - JOUR A1 - El-Khatib, A. H. A1 - Radbruch, H. A1 - Trog, S. A1 - Neumann, B. A1 - Paul, F. A1 - Koch, A. A1 - Linscheid, M. W. A1 - Jakubowski, Norbert A1 - Schellenberger, E. T1 - Gadolinium in human brain sections and colocalization with other elements N2 - Recent recommendations by the Food and Drug Administration1 and the European Medicines Agency2 are to limit the clinical use of linear gadolinium-based contrast agents (GBCAs) due to convincing evidence of deposition in tissues. Macrocyclic GBCA continued to be considered safe, provided that patients have normal renal function. To date, given the low sensitivity of conventional MRI, there has been a debate about the signal increase following the injections of a macrocyclic GBCA. KW - Gadolinium PY - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:b43-471309 SN - 2332-7812 VL - 6 IS - 1 SP - e515, 1 EP - 3 PB - American Academy of Neurology AN - OPUS4-47130 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -